Nanosonics (ASX:NAN) has reported revenue of $203.9 million for the financial year ended 2026, up 3% on FY25, with the cumulative trophon installed base growing 6% to 39,230 devices globally and the CORIS System advancing toward commercial launch throughout FY27, according to the company's Annual Report 2026.
Key Points
- FY26 revenue of $203.9 million, up 3% on FY25, or 6% growth to $211.5 million on a constant currency basis
- Gross profit of $156.8 million with a gross margin of 76.9% for FY26
- Cumulative trophon installed base grew 6% to 39,230 devices globally, protecting approximately 31 million patients each year
- EBIT of $16.0 million, down 10% on FY25, or up 21% to $21.6 million on a constant currency basis
- Cash and cash equivalents of $155.2 million at year end, with FY26 including a share buyback of $20 million
FY26 Financial Results
Nanosonics reported FY26 revenue of $203.9 million compared with $198.6 million in FY25. Gross profit was $156.8 million, against $155.4 million in the prior year. Operating profit before tax was $20.1 million, compared with $22.3 million in FY25. Operating profit after tax was $17.8 million, compared with $20.7 million in FY25. Research and development expenses were $31.8 million in FY26, compared with $34.7 million in FY25. Cash and cash equivalents stood at $155.2 million at the end of FY26, compared with $161.6 million at the end of FY25. The FY26 period included a share buyback of $20 million, according to the filing.
trophon Platform Performance and Installed Base
The cumulative trophon installed base grew 6% to 39,230 devices globally during FY26. According to the filing, the trophon-only business generated EBIT of $50.6 million in FY26, up 5% on the prior corresponding period, or up 16% to $56.5 million on a constant currency basis. The filing states that trophon growth during FY26 was supported by increased total device sales, record upgrade momentum, and continued consumables and services performance. Operating expense growth was limited to 2% through disciplined cost management. Nanosonics Connect and ongoing enhancement of the trophon platform also received investment support from research and development expenditure during the year.
CORIS System Commercial Launch and Regulatory Progress
During FY26, Nanosonics achieved regulatory approvals for the CORIS System, advanced real-world hospital testing, and progressed commercial readiness. The company disclosed that commercial launch of the CORIS System is planned throughout FY27. The CORIS System is described in the filing as an automated technology for flexible endoscope cleaning. The filing states the CORIS System applies automation, validation, compliance, traceability, consumables, service, and workflow change to flexible endoscope reprocessing. Nanosonics operates across North America, Europe, the UK, and Asia Pacific, according to the filing.





Please wait processing your request...